Literature DB >> 24766768

MeCP2: the long trip from a chromatin protein to neurological disorders.

Juan Ausió1, Alexia Martínez de Paz2, Manel Esteller3.   

Abstract

Since the discovery of its fundamental involvement in Rett syndrome, methyl CpG binding protein 2 (MeCP2) has been the focus of an exhaustive biochemical and functional characterization. It is now becoming apparent that the intrinsic highly disordered nature of MeCP2, which is amenable to a plethora of post-translational modifications (PTMs), allows it to recognize a large number of protein interacting partners, including histones. MeCP2 is highly abundant in the brain and it is an important component of neuronal chromatin; nevertheless, the organization and implications of its involvement in terms of DNA methylation binding dependence and effects on transcription are still not well understood. Recent results have shown that MeCP2 plays an important role in brain development, aging, and in neurological disorders.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA methylation; MeCP2; chromatin; intrinsically disordered proteins; neurological disorders

Mesh:

Substances:

Year:  2014        PMID: 24766768     DOI: 10.1016/j.molmed.2014.03.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  40 in total

Review 1.  Striatal morphological and functional alterations induced by prenatal alcohol exposure.

Authors:  Yao-Ying Ma
Journal:  Pharmacol Res       Date:  2019-02-23       Impact factor: 7.658

2.  Developmental timing and critical windows for the treatment of psychiatric disorders.

Authors:  Oscar Marín
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

3.  Functional conservation of MBD proteins: MeCP2 and Drosophila MBD proteins alter sleep.

Authors:  T Gupta; H R Morgan; J A Bailey; S J Certel
Journal:  Genes Brain Behav       Date:  2016-09-06       Impact factor: 3.449

Review 4.  Computational approaches for inferring 3D conformations of chromatin from chromosome conformation capture data.

Authors:  Dario Meluzzi; Gaurav Arya
Journal:  Methods       Date:  2019-08-27       Impact factor: 3.608

5.  Developmental and Thyroid Hormone Regulation of the DNA Methyltransferase 3a Gene in Xenopus Tadpoles.

Authors:  Yasuhiro Kyono; Laurent M Sachs; Patrice Bilesimo; Luan Wen; Robert J Denver
Journal:  Endocrinology       Date:  2016-10-25       Impact factor: 4.736

6.  Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.

Authors:  Katrina V Good; Alexia Martínez de Paz; Monica Tyagi; Manjinder S Cheema; Anita A Thambirajah; Taylor L Gretzinger; Gilda Stefanelli; Robert L Chow; Oliver Krupke; Michael Hendzel; Kristal Missiaen; Alan Underhill; Nicoletta Landsberger; Juan Ausió
Journal:  Epigenetics       Date:  2017-12-05       Impact factor: 4.528

7.  Liganded Thyroid Hormone Receptors Transactivate the DNA Methyltransferase 3a Gene in Mouse Neuronal Cells.

Authors:  Yasuhiro Kyono; Arasakumar Subramani; Preeti Ramadoss; Anthony N Hollenberg; Ronald M Bonett; Robert J Denver
Journal:  Endocrinology       Date:  2016-07-07       Impact factor: 4.736

8.  PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.

Authors:  Navasona Krishnan; Keerthi Krishnan; Christopher R Connors; Meng S Choy; Rebecca Page; Wolfgang Peti; Linda Van Aelst; Stephen D Shea; Nicholas K Tonks
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 9.  Selective repression of gene expression in neuropathic pain by the neuron-restrictive silencing factor/repressor element-1 silencing transcription (NRSF/REST).

Authors:  Dianna E Willis; Meng Wang; Elizabeth Brown; Lilah Fones; John W Cave
Journal:  Neurosci Lett       Date:  2015-12-08       Impact factor: 3.046

Review 10.  Epigenetic mechanisms in schizophrenia.

Authors:  Kimberly R Shorter; Brooke H Miller
Journal:  Prog Biophys Mol Biol       Date:  2015-05-07       Impact factor: 3.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.